Skip Nav Destination
Issues
1 February 2013
-
Cover Image
Cover Image
Immunosuppressive drugs are thought to cause the dramatically increased risk of carcinomas in sun-exposed skin of organ transplant recipients. However, the drugs differ in local effects on the skin and may thus be predictive of skin cancer risk and potentially provide guidance in minimizing the risk. In this study, the tumorigenic properties of commonly used immunosuppressants (e.g., azathioprine, cyclosporine, and rapamycin) were compared in experiments using human skin and mouse models. The cover shows a representative H&E-stained image of human skin equivalents (HSE) supplemented with rapamycin (100 nM) for a 2-week duration. Rapamycin reduced the epidermis that developed in the HSE: 3 to 4 epidermal cell layers were formed instead of 7 to 8 in the Control HSE supplemented with dimethyl sulfoxide (DMSO) (not shown). Rapamycin also decreased the proliferation index and expression of hyperproliferative markers K16 and K17 (not shown). These experiments established whether local effects of immunosuppressants on UV-induced apoptosis and p53 mutations in the skin are predictive of skin cancer risk. See article by Voskamp and colleagues (beginning on page 129) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Commentary
Research Articles
A Randomized, Placebo-Controlled, Preoperative Trial of Allopurinol in Subjects with Colorectal Adenoma
Matteo Puntoni; Daniela Branchi; Alessandra Argusti; Silvia Zanardi; Cristiano Crosta; Emanuele Meroni; Francesco Munizzi; Paolo Michetti; Gianni Coccia; Giuseppe De Roberto; Roberto Bandelloni; Laura Turbino; Egle Minetti; Marco Mori; Sandra Salvi; Simona Boccardo; Beatrice Gatteschi; Roberto Benelli; Angelica Sonzogni; Andrea DeCensi
Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Marian L. Neuhouser; Elizabeth A. Platz; Cathee Till; Catherine M. Tangen; Phyllis J. Goodman; Alan Kristal; Howard L. Parnes; Yuzhen Tao; William D. Figg; M. Scott Lucia; Ashraful Hoque; Ann W. Hsing; Ian M. Thompson; Michael Pollak
Endobronchial miRNAs as Biomarkers in Lung Cancer Chemoprevention
Celine Mascaux; William J. Feser; Marina T. Lewis; Anna E. Barón; Christopher D. Coldren; Daniel T. Merrick; Timothy C. Kennedy; John I. Eckelberger; Leslie M. Rozeboom; Wilbur A. Franklin; John D. Minna; Paul A. Bunn; York E. Miller; Robert L. Keith; Fred R. Hirsch
Prolonged Biologically Active Colonic Tissue Levels of Curcumin Achieved After Oral Administration—A Clinical Pilot Study Including Assessment of Patient Acceptability
Glen R.B. Irving; Lynne M. Howells; Stewart Sale; Ines Kralj-Hans; Wendy S. Atkin; Susan K. Clark; Robert G. Britton; Donald J.L. Jones; Edwina N. Scott; David P. Berry; David Hemingway; Andrew S. Miller; Karen Brown; Andreas J. Gescher; William P. Steward
Dietary Immunosuppressants Do Not Enhance UV-Induced Skin Carcinogenesis, and Reveal Discordance between p53-Mutant Early Clones and Carcinomas
Pieter Voskamp; Carolien A Bodmann; Gudrun E Koehl; Heggert G. Rebel; Marjolein G.E. Van Olderen; Andreas Gaumann; Abdoel El Ghalbzouri; Cornelis P. Tensen; Jan N. Bouwes Bavinck; Rein Willemze; Edward K. Geissler; Frank R. De Gruijl
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.